Q-omics provides the consensus-scored OTUD4P1 profile across patient tissues and cancer cell-line models. OTUD4P1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, OTUD4P1 is differentially expressed in 5, with the highest sampling consensus in THCA. Additionally, OTUD4P1 RNA expression shows 17,352 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight HNSC, THCA, and THYM as cancer lineages where OTUD4P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OTUD4P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OTUD4P1 survival associations across molecular data types. OTUD4P1 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OTUD4P1 RNA expression–survival associations across cancer types. High OTUD4P1 expression shows unfavorable associations in MESO, but favorable associations in HNSC, SKCM, KIRC, BRCA and READ. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify HNSC as the clearest survival context for OTUD4P1 RNA expression.
This table summarizes OTUD4P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5, while mass-spec protein shows differences in 1. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for OTUD4P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OTUD4P1 shows lower tumor expression in THCA, BRCA and KICH and higher tumor expression in COAD and LIHC. The THCA box plot shows higher OTUD4P1 RNA expression in normal versus tumor tissue (log2 FC = −0.092, t-test p < 0.001).
This table shows molecular features associated with OTUD4P1 in patient tissues and cancer cell lines. In patient samples, OTUD4P1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
